A Phase II Trial of Atezolizumab and Bevacizumab in Cisplatin-ineligible Patients with Advanced/Unresectable Urothelial Cancer

Publications: 

• AV Balar, SA Funt, S Gupta, AZ Dudek, AR Boiles, DA Vanea, D Kilari, JE Rosenberg. Hcrn GU15-215: A phase II trial of atezolizumab (atezo) and bevacizumab (bev) in cisplatin-ineligible patients (pts) with advanced/unresectable urothelial cancer (UC). Presented as at ASCO Annual Meeting 2020. See abstract.

Learn more:

• clinicaltrials.gov: #NCT03272217
• News release